We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GB
101
DELISTED
Global Blue Group Holding
GB
$8.42M 0.11%
1,214,475
– –
CRSP icon
102
CRISPR Therapeutics
CRSP
$5.17B
$8.19M 0.11%
208,000
+8,000
+4% +$378K
ANGO icon
103
AngioDynamics
ANGO
$649M
$7.99M 0.11%
872,000
-90,000
-9% -$662K
RH icon
104
RH
RH
$3.71B
$7.85M 0.11%
+19,941
New +$7.09M
CPNG icon
105
Coupang
CPNG
$29.2B
$7.84M 0.11%
+356,872
New +$8.76M
CMRX
106
DELISTED
Chimerix, Inc.
CMRX
$7.78M 0.11%
2,236,000
+28,000
+1% +$39.5K
LVS icon
107
Las Vegas Sands
LVS
$29.6B
$7.68M 0.1%
149,614
-25,486
-15% -$1.32M
SCLX icon
108
Scilex Holding
SCLX
$48.9M
$7.62M 0.1%
510,782
+410,496
+409% +$10.4M
VERA icon
109
Vera Therapeutics
VERA
$2.36B
$7.54M 0.1%
+178,283
New +$7.89M
BBY icon
110
Best Buy
BBY
$17.3B
$7.52M 0.1%
+87,677
New +$8M
TGT icon
111
Target
TGT
$68B
$7.51M 0.1%
55,523
+10,150
+22% +$1.45M
PATH icon
112
UiPath
PATH
$7.8B
$7.14M 0.1%
561,907
+71,292
+15% +$942K
FWRG icon
113
First Watch Restaurant Group
FWRG
$766M
$6.98M 0.1%
+375,000
New +$6.63M
EAT icon
114
Brinker International
EAT
$9.66B
$6.68M 0.09%
50,528
-102,628
-67% -$11.6M
NPCE icon
115
Neuropace
NPCE
$506M
$6.63M 0.09%
592,614
+112,614
+23% +$979K
AZN icon
116
AstraZeneca
AZN
$250B
$6.55M 0.09%
+50,000
New +$7M
VRCA icon
117
Verrica Pharmaceuticals
VRCA
$87.3M
$6.24M 0.09%
+892,100
New +$9.81M
RMTI icon
118
Rockwell Medical
RMTI
$28.2M
$6.21M 0.08%
304,368
-53,785
-15% -$1.57M
CMG icon
119
Chipotle Mexican Grill
CMG
$41.5B
$6.02M 0.08%
99,869
-250,949
-72% -$15.1M
MURA
120
DELISTED
Mural Oncology
MURA
$5.47M 0.07%
1,700,000
– –
ORLY icon
121
O'Reilly Automotive
ORLY
$76.3B
$5.35M 0.07%
67,725
-31,215
-32% -$2.52M
VNRX icon
122
VolitionRx Ltd
VNRX
$9.34M
$5.09M 0.07%
424,095
-25,841
-6% -$347K
LW icon
123
Lamb Weston
LW
$7.19B
$5.06M 0.07%
+75,733
New +$5.65M
SYRE icon
124
Spyre Therapeutics
SYRE
$9.25B
$4.66M 0.06%
200,000
+64,000
+47% +$1.88M
APLE icon
125
Apple Hospitality REIT
APLE
$3.82B
$4.21M 0.06%
+274,407
New +$4.25M
3 4
5
6 7

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.